Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

IND.216 - A Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia - was closed to further accrual on January 24, 2017 as it met its targeted accrual.

Thank you to all participating centres, staff and patients for your contributions to this study.